Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Farmatsiya i Farmakologiya ; 10(6):573-588, 2022.
Article in English | EMBASE | ID: covidwho-2251079


Currently, there are data that that make it possible to speak about a high clinical efficacy of the use of succinic salt of tyrosylD-alanyl-glycyl-phenylalanyl-leucyl-arginine (hexapeptide succinate) for the COVID-19 treatment. This article is devoted to the results of clinical trials of the original Russian drug based on it. The aim of the study was to evaluate a clinical efficacy, safety and tolerability of intramuscular and inhalation use of hexapeptide succinate in complex therapy in comparison with standard therapy in patients with moderate COVID-19. Materials and methods. The research was conducted from February 28, 2022 to November 22, 2022 based on 10 research centers in the Russian Federation. The study included hospitalized patients (n=312) over 18 years of age with moderate COVID-19 who had undergone a screening procedure and were randomized into 3 groups: group 1 received standard therapy in accordance with the Interim Guidelines in force at the time of the study, within 10 days;group 2 received hexapeptide succinate (Ambervin Pulmo) intramuscularly at the dose of 1 mg once a day for 10 days;group 3 received hexapeptide succinate (Ambervin Pulmo) 10 mg once a day by inhalation for 10 days. Results. According to the results of the study, therapy with the drug hexapeptide succinate, both intramuscular and inhaled, provided an acceleration of recovery up to the complete absence of the disease signs in more than 80% of hospitalized COVID-19 patients. By the end of the therapy course with the drug, more than 60% of patients had met the criteria for discharge from hospital and could continue the treatment on an outpatient basis. About 70% of patients in the inhalation group and 80% in the intramuscular hexapeptide succinate injection group had concomitant diseases (hypertension - 28%, obesity - 14%), which indicates the effectiveness of this drug use in comorbid patients. The use of the drug contributed to the restoration of damaged lung tissues, normalization of oxygenation, the disappearance of shortness of breath and a decrease in the duration of the disease symptoms compared with standard therapy. As a result of a comparative analysis of adverse events in terms of their presence, severity, causal relationship with the therapy and outcome, there were no statistically significant differences between the treatment groups. Conclusion. Thus, the results of the clinical study of the succinate hexapeptide efficacy and safety showed the feasibility of using the drug in pathogenetic therapy COVID-19 regimens.Copyright © 2022 Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute. All rights reserved.

Flebologiya ; 16(2):122-129, 2022.
Article in Russian | EMBASE | ID: covidwho-1887364


Objective. To analyze the incidence, structure, course and outcomes of venous thromboembolism (VTE) in patients with a novel coronavirus infection (COVID-19) during the first and the second waves of the pandemic, to identify and evaluate the features of laboratory data. Material and methods. We assessed instrumental and laboratory data in COVID-19 patients during the first (1839 patients) and the second (840 patients) waves of the pandemic. Mortality, localization of thrombosis, variants of anticoagulation and laboratory data (leukocytes, C-reactive protein, fibrinogen, ferritin) were analyzed. Results. VTE occurred in 27 (1.5%) and 13 (1.5%) patients with a novel coronavirus infection during the first and the second waves of the pandemic, respectively. In the first wave, thromboembolic events included deep vein thrombosis (DVT) in 16 (59%) cases, pulmonary embolism (PE) in 6 (22%) cases, DVT + PE in 2 (8%) patients, saphenous vein thrombophlebitis in 3 (11%) cases. In the second wave, DVT was detected in 5 (38.5%) patients, DVT+PE in 5 (38.5%) cases, PE without DVT in 2 (15.4%) patients and thrombosis of the right renal vein in 1 (7.6%) patient. In the first wave, mean leukocyte count was 9.2 x 109/L (6.9—14.3), C-reactive protein — 77.5 mg/L (26-159), fibrinogen — 593.5 mg/ml (500—700), ferritin — 1132.6 µ/L (165-1753). The second wave of the pandemic was characterized by moderate leukocytosis (12.2·109 /L (7—19)), increase of serum fibrinogen (544 mg/ ml (405—781)), C-reactive protein (102.75 mg/L (80—163)) and ferritin (510 μg/L (230—566)). Conclusion. VTE in patients with a new coronavirus infection is followed by high mortality. In the second wave of the pandemic, mortality of patients with VTE was higher that may be associated with both thrombotic complications and cardiovascular comorbidities.